文献速递肝病消化道肿瘤与早癌消化内镜

肿瘤负荷评分预测肝细胞癌TACE后肝外进展:多中心观察性研究

Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study.
PubMed 文献 · Aliment Pharmacol Ther · 2026-01-14

基于ITA.LI.CA数据库纳入890例一线TACE的HCC患者,评估肝外进展(EHP)发生率及肿瘤负荷评分(TBS)的预测作用。TBS最佳截点为3.66,TBS高组首次进展时EHP(10.4% vs 3.6%)和总体EHP(32.6% vs 18.7%)均显著高于低组,TBS高与AFP是EHP独立预测因素。

要点

  • TACE后EHP总体发生率26.1%,首次进展时EHP为7.2%。
  • TBS截点3.66,高TBS组EHP风险显著更高且生存更短。
  • TBS联合AFP可准确分层TACE后EHP风险。

核心结论

  • TACE治疗的HCC患者肝外播散不常见,TBS计算简便且有助于识别转移高风险患者。

研究设计与样本

  • 来自ITA.LI.CA数据库的多中心观察性研究,纳入890例接受一线TACE的HCC患者。

主要发现

  • TACE后7.2%患者首次进展时发生EHP,随访期间总体EHP率为26.1%。
  • TBS最佳截点为3.66,TBS高组(>3.66)首次进展时EHP为10.4% vs 低组3.6%(p<0.001)。
  • TBS高组总体EHP为32.6% vs 低组18.7%(p<0.001)。
  • TBS高组无进展生存期和总生存期更短。
  • TBS高与AFP水平是首次进展时及随访期间EHP的独立预测因素,联合评估可准确分层EHP风险。

关键数值与推荐

  • TBS最佳截点为3.66,高TBS定义为>3.66。
  • 首次进展时EHP:TBS高组10.4% vs 低组3.6%(p<0.001)。
  • 总体EHP:TBS高组32.6% vs 低组18.7%(p<0.001)。

临床怎么用

  • 对接受TACE的HCC患者计算TBS,TBS>3.66提示肝外进展风险较高。
  • 结合AFP水平可进一步分层EHP风险,辅助随访监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with hepatocellular carcinoma (HCC), extrahepatic progression (EHP) has a known dismal meaning. We evaluated the incidence and risk factors of EHP in HCC patients treated with transarterial chemoembolization (TACE), and the predictive role of tumour burden. METHODS: From the ITA.LI.CA database, 890 HCC patients undergoing first-line TACE were included. Tumour burden score (TBS) was calculated and, after identification of the best cut-point value, incidence and predictors of EHP were compared between TBS-low and TBS-high groups. Independent predictors of EHP at the first progression episode or at any time during follow-up were identified through multivariable Cox analysis. RESULTS: After TACE, 7.2% of patients experienced EHP at the first progression episode, while the overall EHP rate during the follow-up was 26.1%. The best cut-point for TBS was 3.66. TBS-high group (> 3.66) showed a significantly higher proportion of EHP both at first progression (10.4% vs. 3.6%; p < 0.001) and overall (32.6% vs. 18.7%; p < 0.001) compared to the TBS-low group. Moreover, TBS-high patients had shorter progression-free survival and overall survival. TBS-high and AFP levels emerged as independent predictors of EHP at the first progression episode and during the follow-up, and their combined evaluation accurately stratified patients for their risk of EHP. CONCLUSION: Extrahepatic dissemination is infrequent in HCC patients treated with TACE. TBS is easily calculable and helps in identifying patients at higher risk of metastasis development.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pinto E, Pelizzaro F, Simeon V, et al. Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study. Aliment Pharmacol Ther. 2026. PMID: 41531314. doi:10.1111/apt.70534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。